Pichardo-Bahena R, Barredo-Prieto BA, Almeda-Valdés P, Chavez-Tapia NC, Méndez-Sánchez N

Language: Spanish
References: 22
Page: 175-178
PDF size: 48.99 Kb.

ABSTRACT

Background: Helicobacter pylori infection has been related with the development of Barrett´s metaplasia, gastric metaplasia and esophageal carcinoma. However, its role is incompletely understood. The question is even greater when other factors such as the presence of inflammation and its degree are taken in account. Methods: biopsies from Barrett´s epithelium y gastric metaplasia were evaluated to determine Helicobacter pylori infection severity of inflammation. Objective: To describe a case-series with Barrett´s epithelium and gastric metaplasia to determine the presence and everity of the Helicobacter pylori infection and the presence and degree of chronic or acute inflammation. Results: the presence of Helicobacter pylori infection in patients with Barrett´s epithelium and gastric metaplasia is of 76.5% and 61.1% respectively. The prevalence of inflammation and its severity are also related with Helicobacter pylori infection. Conclusions: There is a high prevalence of Helicobacter pylori infection in patients with Barrett´s epithelium and gastric metaplasia and it is associated with greater severity inflammation. Helicobacter pylory may have a role in the genesis or as an adjuvant on the development of Barrett´s epithelium.

REFERENCES

1. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol Suppl 1996; 215: 48-51.

2. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997; 41: 277-80.

3. Spechler SJ. Clinical practice. Barrett’s Esophagus. N Engl J Med 2002; 346: 836-42.

4. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333-8.

5. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett’s oesophagus. Gut 1997; 40: 9-13.

6. Paull G, Yardley JH. Gastric and esophageal Campylobacter pylori in patients with Barrett’s esophagus. Gastroenterology 1988; 95: 216-8.

7. Talley NJ, Cameron AJ, Shorter RG, Zinsmeister AR, Phillips SF. Campylobacter pylori and Barrett’s esophagus. Mayo Clin Proc 1988; 63: 1176-80.

8. Loffeld RJ, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett’s esophagus. Am J Gastroenterol 1992; 87: 1598-600.

9. Vicari JJ, Peek RM, Falk GW et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.

10. Pena AS, Pajares JM, Malfertheiner P. Helicobacter pylori and gastroduodenal pathology: 3rd Annual international workshop: Papers, 1993.

11. Hunt RH, Tytgat GNJ. Helicobacter pylori: basic mechanisms to clinical cure: proceedings of the International Symposium held at Amelia Island, Florida, USA, November 3-6, 1993. Dordrecht; London: Kluwer, 1994.

12. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ. The increasing frequency of adenocarcinoma of the esophagus. Cancer 1989; 64: 526-30.

13. Almeda-Valdés P, Hernández-Martínez B, R P-B, Morán Consuelos MA, J L-C. Hallazgos histológicos en las biopsias de pacientes sometidos a panendoscopia en el Hospital Médica Sur. Med Int Mex 2003; 19.

14. Torrado J, Ruiz B, Garay J et al. Blood-group phenotypes, sulfomucins, and Helicobacter pylori in Barrett’s esophagus. Am J Surg Pathol 1997; 21: 1023-9.

15. Henihan RD, Stuart RC, Nolan N, Gorey TF, Hennessy TP, O’Morain CA. Barrett’s esophagus and the presence of Helicobacter pylori. Am J Gastroenterol 1998; 93: 542-6.

16. Bowrey DJ, Williams GT, Clark GW. Interactions between Helicobacter pylori and gastroesophageal reflux disease. Dis Esophagus 1998; 11: 203-9.

17. Abbas Z, Hussainy AS, Ibrahim F, Jafri SM, Shaikh H, Khan AH. Barrett’s oesophagus and Helicobacter pylori. J Gastroenterol Hepatol 1995; 10: 331-3.

18. Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994; 29: 425-9.

19. Wilson KT, Ramanujam KS, Mobley HL, Musselman RF, James SP, Meltzer SJ. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastroenterology 1996; 111: 1524-33.

20. Farthing MJ, Fitzgerald R, Zhang ZW. Acid, Helicobacter and immunity: a new paradigm for oesophagogastric cancer. J Physiol Paris 2001; 95: 423-7.

21. Lan J, Xiong YY, Lin YX et al. Helicobacter pylori infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation. World J Gastroenterol 2003; 9: 54-8.

22. Walker SJ, Birch PJ, Stewart M, Stoddard CJ, Hart CA, Day DW. Patterns of colonization of Campylobacter pylori in the oesophagus, stomach and duodenum. Gut 1989; 30: 1334-8.